Day 1 :
French National Institute of Health, France
Time : 09:30-10:05
Dr. Alvaro Macieira-Coelho is a Research Director at the French National Institute of Health. He received an MD from the University of Lisbon, Portugal, and a PhD from the University of Uppsala Sweden. He made an internship at the University Hospital in Lisbon and was a research associate at the Wistar Institute in Philadelphia (USA) and at the Department of Cell Biology of the University of Uppsala (Sweden). He became Head of the Department of Cell Pathology at the Cancer Institute in Villejuif (France) and was a visiting Professor at the University of Linkoping (Sweden). He published 150 papers in professional Journals and 9 books on cancer and aging. He received the following awards: Fritz Verzar Prize (University of Vienna, Austria), “Seeds of Science”, Career Prize (Lisbon, Portugal), Dr. Honoris Causa (University of Linkoping, Sweden), Johananof International Visiting Professor (Institute Mario Negri, Milano, Italy).
Most of the scientific literature reports that aging favors the development of cancers. Each type of cancer, however, initiates and evolves differently and their natural history can start way back at earlier ages before their clinical manifestations. The incidence of cancers is spread through the human life span, it is the result of pre- and post-natal aggressions, individual susceptibility, and developmental changes that evolve continuously from the beginning to the end. Finally during human senescence the incidence declines for all cancers. Frequently the progression of cancers is also slower in the old. There are several possible explanations for this decline. It is time to ask why some tumors are characteristic of the young, others of maturity, others of the time of the decline of the reproductive period, and finally why the incidence of cancers declines late during senescence of the human organism. These questions should be answered before the origin of cancers can be understood.
Mount Sinai School of Medicine, USA
Time : 10:05-10:40
Liane Deligdisch has completed her graduation from Medical School in Bucharest, Romania. She was Gynecologist and General Physician in Romania until 1963, Pathologist at the Ichilov Hospital, Tel Aviv Medical School, Israel from 1963 to 1975. She was visiting Professor at Magee Women Hospital in Pittsburgh and Boston Free Hospital for Women. She is currently visiting Professor at Harvard Medical School. She founded the division of Gynecologic Pathology and directed the course of Gynecologic Pathology at the Medical School, authored 143 peer reviewed articles, seven textbooks on Gynecologic Pathology.
Ovarian Carcinoma (OC) is the most lethal gynecologic neoplasm due to late stage diagnosis. The rare cases of OC diagnosed in stage one have an 85% five year survival while all stage OC survival is 32%, due to the late diagnosis of mostly asymptomatic OC and to lack of reliable tumor markers in early stages. Recently other malignant tumors with systematic early detection and precursor stage identification have a favorable outcome. For OC morbidity and mortality statistics have not changed much over the past five decades. Our clinical-pathologic studies revealed that serous OC, the most numerous overall, represent a minority (less than 1/3) of stage one OC. Early diagnosed OC occur in younger patients with associated symptomatic pathology related to hyperestrogenism, endometriosis, endometrial hyperplasia and neoplasia, infertility and endometrioid, mucinous and clear cell carcinomas. Early diagnosed serous carcinomas, often asymptomatic, affect older patients, some BRCA positive, with personal and family histories of breast cancer undergo frequent medical examinations that may intercept aggressive OC in early stages. Prophylactic salpingo-oophorectomy specimens revealed in statistically significant numbers preinvasive histological changes in ovaries and fallopian tube fimbriae. Morphometric (computerized image analysis), immunohistologic and molecular testing offering an insight into early carcinogenesis of OC. Ongoing studies of cancer stem cells in addition are aimed at identifying more diagnostic and therapeutic strategies for OC.
SIMFO GmbH, Germany
Keynote: Maintrac® CTC detection as a tool to uncover the strategies of tumor cells to evade elimination
Time : 11:00-11:35
Prof. Dr. med. Katharina Pachmann is Senior Researcher at Transfusion Center Bayreuth, Germany since 2012. She is the Head of Marketing Oncology CTCs at SIMFO GmbH .She recevied her Phd from Institute for Hematology der GSF, München; Medical Clinic, Klinikum rechts der Isar, München; Medical Clinic, Klinikum Innenstadt der Ludwig-Maximilians Universität, München respectively. She also served as the Head of the Department of Experimental Hematology and Oncology, Friedrich Schiller-Universität Jena. She is visiting scientist at LKH Universitätsklinikum Graz Gemeinsame Einrichtung für Klinische Immunologie, Jean-Dausset Laboratorium. She has also served as a Visiting Scientist in MD Anderson Cancer Center Houston Texas Section of Molecular Hematology and Therapy from 1996-1998.
The most fearful feature of malignant tumors is their ability to form distant metastases in vital organs leading to fatal outcome, therefore the most important task of tumor therapy is the prevention of metastasis formation. Metastases develop from cells that leave the tumor and travel via the blood until they find a niche to settle and grow. Different measures have been applied to detect tumors by screening before they might seed cells, destroy the disseminated cells by neoadjuvant and adjuvant chemotherapy and/or prevent them from regrowing by surveillance after primary therapy. However, all these actions are taken without being able to directly control to what extent they influence tumor cell dissemination. The maintrac® approach enables physicians and patients to timely and individually determine the effect of different therapeutic actions on dissemination and elimination from blood and to monitor the behavior of the circulating tumor cells during the whole course of disease by enumerating these cells at any time of point of the disease. Assumptions which have not been explainable before now can be confirmed by direct observation of the behavior of the circulating tumor cells. Surgery can lead to convey metastasis formation because it leads to tumor cell dissemination and activation. Chemotherapy is effective only in a fraction of patients because in some patients the circulating tumor cells become resistant against the drugs and can regrow in their presence. Hormone blocking silences the circulating tumor cells but in most cases is not able to eliminate them so they can regrow after stopping treatment. And finally, we are able to show that the circulating tumor cells can upregulate ligands which prevent immune cells from recognizing them. Thus, this method will in the future contribute to take action at the time when treatment shows insufficient effect and thus optimally tailor tumor therapy.